At a glance
ClinicalIndex Comparison RecordN/ACompleted· 412 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COSMOS - COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
In Brief
An observational study for Parkinson's Disease (PD). Completed, enrolled 412 participants across 30 sites in 11 countries.
Detailed Summary
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease (PD)
CountriesAustria, Canada, Croatia, Czechia, Greece, Hungary, Ireland, Israel, Romania, Spain, Sweden
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartDec 2017
Primary CompletionDec 2018
TodayJul 2026
First PostedDec 5, 2017
Enrollment StartDec 14, 2017
Primary CompletionDec 17, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.6 years ago